SCHEMBL4118564

SCHEMBL4118564

CCc1cccc(NC(=O)Nc2ccc([N+](=O)[O-])cc2)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.73
MEN1 O00255 10/20 0.62
KMT2A Q03164 10/20 0.62
MAPT P10636 7/20 0.60
HTT P42858 2/20 0.60
POLB P06746 2/20 0.60
DDX3X O00571 1/20 0.60
CTDSP1 Q9GZU7 1/20 0.60
BAZ1A Q9NRL2 1/20 0.57
RAB9A P51151 4/20 0.56
KDR P35968 1/20 0.56
NPC1 O15118 4/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
MAPK1 P28482 2/20 0.56
LMNA P02545 1/20 0.56
ALOX15 P16050 1/20 0.55
CA12 O43570 1/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
CA5A P35218 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4122859 0.86 MEN1 (0.73) GAAMEN1KMT2AMAPTHTT
SCHEMBL28155299 0.86 MEN1 (0.62) GAAMEN1KMT2AMAPTHTT
SCHEMBL11047722 0.86 MEN1 (0.74) GAAMEN1KMT2AMAPTHTT
SCHEMBL4124277 0.86 MEN1 (0.74) GAAMEN1KMT2AMAPTHTT
SCHEMBL4104375 0.84 RAB9A (0.71) GAAMEN1KMT2AMAPTHTT
SCHEMBL12314444 0.83 GAA (0.64) GAAMEN1KMT2AMAPTRAB9A
SCHEMBL4105876 0.81 RAB9A (0.63) GAAMEN1KMT2AMAPTRAB9A
SCHEMBL4117970 0.81 MEN1 (0.62) GAAMEN1KMT2AMAPTHTT
SCHEMBL709156 0.80 MEN1 (0.70) GAAMEN1KMT2AMAPTHTT
SCHEMBL8956783 0.80 MEN1 (0.64) MEN1KMT2AMAPTHTTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 GAA 2000/4885MEN1 3273/4885KMT2A 2807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.